Clinical Trial Update: A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia [Phase 3]

View source ↗

Summary

Phase III study PA21 in peritoneal dialysis patients with hyperphosphatemia has completed, with the trial status updated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• PA21 (PA21)

Snippet

Sponsor: Kissei Pharmaceutical Co., Ltd. | Conditions: Peritoneal Dialysis, Hyperphosphatemia | Phase 3 | Status: COMPLETED